Renal drug handing and drug-drug interactions in ADMET

Led by Dr Colin Brown, Newcells Biotech has licensed-in an in vitro ADMET assay platform from Newcastle University to determine how new drugs are transported by the kidney.

The assays currently offered are based on human or animal cells transfected to express single or dual human kidney transporters on their surfaces. The major limitation is that they do not accurately reflect the situation in vivo where there may be more than one transporter involved in the drug handling or when there is competition with other drug molecules. Therefore, this does not accurately predict drug handling or nephrotoxicity in the clinical setting.

Dr Brown is the leading expert on drug transport in human kidney and has optimised a primary kidney proximal tubule cell (KPTC) model for the investigation of drug handling and nephrotoxicity (the a-Proximate system). The a-Proximate system is available using primary human, rat or mouse KPTC. The a-Proximate system offers a superior alternative to commercially available cloned transporter assays as it can be used to accurately predict renal drug handling and drug-drug interactions prior to clinical trials.

You might also be interested in…
retinal pigmented epithelium (RPE)
Blog

Newcells Biotech Ltd. RPE Model to Improve Drug Retinal Toxicity Assessment

Retinal toxicity is an adverse side effect that can cause (usually irreversible) deterioration of a person’s vision, when taking certain medication. This has been seen for example in people taking Hydroxychloroquine for Malaria due to toxicity to the retinal cells.  The retinal pigmented epithelium (RPE) is